NCT02589548

Brief Summary

The study is a prospective registry of Hodgkin Lymphoma (HL) patients in Brazil. The purpose of the study is to gather clinical, epidemiologic and outcomes data on the treatment of HL, on the basis of records collected by key Brazilian institutions, through a centralized web-based registry of clinical data verified by central board of hematopathologists.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,400

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2009

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2009

Completed
6.1 years until next milestone

First Submitted

Initial submission to the registry

October 26, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 28, 2015

Completed
7.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

May 17, 2022

Status Verified

May 1, 2022

Enrollment Period

13.2 years

First QC Date

October 26, 2015

Last Update Submit

May 16, 2022

Conditions

Hodgkin LymphomaHodgkin Disease

Keywords

Hodgkin LymphomaHodgkin Disease

Outcome Measures

Primary Outcomes (1)

  • Overall Survival

    Overall Survival

    5 years

Secondary Outcomes (1)

  • Event Free survival

    5 years

Eligibility Criteria

Age12 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hodgkin Lymphoma patients

You may qualify if:

  • Previously untreated HL patients
  • Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 5 years are requested
  • Written informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidade Federal Do Rio de Janeiro

Rio de Janeiro, 21941-913, Brazil

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Formalin-fixed tissue for central diagnostic pathology review

MeSH Terms

Conditions

Hodgkin Disease

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Officials

  • Nelson Spector, MD

    UFRJ

    STUDY CHAIR

  • Irene Biasoli

    UFRJ

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nelson Spector, MD

CONTACT

+552139382460spector@ufrj.br

Irene Biasoli, MD

CONTACT

+552139382460irene.biasoli@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 26, 2015

First Posted

October 28, 2015

Study Start

October 1, 2009

Primary Completion

December 1, 2022

Study Completion

December 1, 2022

Last Updated

May 17, 2022

Record last verified: 2022-05

Locations

BR(1)